

Special Issue

Recent Vaccine Development for Emerging Infectious Diseases

Message from the Guest Editors

Emerging infectious diseases are infections that have recently appeared within a population or those whose incidence or geographic range is rapidly increasing or threatens to increase in the near future. Emerging infections can be caused by previously unknown infectious agents, known agents that have spread to new geographic locations or new populations, or the re-emergence of agents whose incidence of disease had significantly declined in the past, but whose incidence has reappeared. The world is continuously facing the threats of emerging infectious diseases. COVID-19 has affected over 200 countries of the world and severely affected the healthcare and financial systems of both developed and developing countries. Monkeypox infections are also being reported from different countries and there has been a recent increase in cases of Ebola virus in Uganda. There is a strong need to understand the threats of emerging infectious diseases and have an effective global plan to develop vaccines for these diseases.

Guest Editors

Prof. Dr. Yasir Waheed

Office of Research, Innovation and Commercialization (ORIC), Shaheed Zulfikar Ali Bhutto Medical University (SZABMU), Islamabad 44000, Pakistan

Dr. Khalid Muhammad

Department of Biology, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/148512

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).